KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Receivables - Other (2018 - 2021)

Historic Receivables - Other for Alnylam Pharmaceuticals (ALNY) over the last 3 years, with Q2 2021 value amounting to $500.0 million.

  • Alnylam Pharmaceuticals' Receivables - Other changed N/A to $500.0 million in Q2 2021 from the same period last year, while for Jun 2021 it was $500.0 million, marking a year-over-year change of. This contributed to the annual value of $500.0 million for FY2020, which is N/A changed from last year.
  • Per Alnylam Pharmaceuticals' latest filing, its Receivables - Other stood at $500.0 million for Q2 2021.
  • Over the past 5 years, Alnylam Pharmaceuticals' Receivables - Other peaked at $500.0 million during Q3 2020, and registered a low of $12.5 million during Q4 2018.
  • Moreover, its 3-year median value for Receivables - Other was $500.0 million (2020), whereas its average is $402.5 million.